Cardiometabolic Diseases Global Market Report 2025
상품코드:1824346
리서치사:The Business Research Company
발행일:On Demand Report
페이지 정보:영문 250 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
세계의 심장대사 질환 시장 규모는 향후 수년간 안정된 성장이 예상됩니다. 2029년까지 연평균 복합 성장률(CAGR) 4.4%로 확대되어 1,369억 5,000만 달러로 성장할 것으로 보입니다. 예측 기간의 성장은 비만의 유행, 노화 지속, 건강 관리 인프라 개발, 유전체 의료 및 정밀의료, 만성 스트레스 및 정신 건강에 기인한다고 생각됩니다. 예측기간의 주요 동향으로는 건강교육과 의식 향상, 기업의 웰니스 프로그램, 지역의 건강 프로그램, 예방 중심의 헬스케어, 통합 케어 접근법 등이 있습니다.
향후 5년간의 성장률 4.4%라는 예측은 지난 예측으로부터 0.1% 소폭 감소를 반영하고 있습니다. 이 감소는 주로 미국과 다른 국가 간의 관세의 영향 때문입니다. 관세의 부과는 독일과 핀란드에서 수입되는 지속 혈당 모니터 및 리포단백질 검사 시약의 비용을 증가시키고 당뇨병 및 심혈관 결과를 악화시킬 수 있으므로 미국의 예방 의료를 혼란시킬 수 있습니다. 또한 상호관세와 무역의 긴장과 한계 증가로 인한 세계 경제와 무역에 대한 악영향으로 인해 그 영향이 보다 광범위하게 이어질 수 있습니다.
비만률의 급증은 심장대사 질환 시장의 성장을 가속하는 중요한 요인이 될 것으로 예측됩니다. 비만은 체중 증가로 이어지는 체지방의 과잉 축적을 특징으로 하며, 지질 이상증, 2형 당뇨병, 고혈압, 수면장애 등 심혈관 위험 인자의 유병률에 크게 영향을 미칩니다. 2022년 3월 세계보건기구(WHO)가 보고한 바와 같이, 전 세계적으로 매년 3억 4천만 명의 청년, 6억 5천만 명의 성인, 3,900만 명의 소아를 포함한 10억 명 이상이 비만과 싸우고 있습니다. WHO는 2025년까지 1억 6,700만 명의 성인과 어린이가 과체중과 비만으로 인한 건강 합병증에 직면할 것으로 예측됩니다. 이러한 비만이 높은 확산은 심장대사 질환 시장의 성장을 가속하는 매우 중요한 요소입니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 심장대사 질환 시장 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 이용 산업의 분석
세계의 심장대사 질환 시장 : 성장률 분석
세계의 심장대사 질환 시장 실적 : 규모와 성장, 2019-2024년
세계의 심장대사 질환 시장 예측 : 규모와 성장, 2024-2029년, 2034년
세계의 심장대사 질환 시장 : 총 시장 규모(TAM)
제6장 시장 세분화
세계의 심장대사 질환 시장 : 유형별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
만성 심부전 및 충혈성 심부전
고혈압
2형 당뇨병
비만
세계의 심장대사 질환 시장 : 치료별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
ACE 억제제
이뇨제
글루코파지
지방흡입
기타
세계의 심장대사 질환 시장 : 투여별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
정제
주사
세계의 심장대사 질환 시장 : 투여 경로별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
경구
정맥내
기타
세계의 심장대사 질환 시장 : 최종 사용자별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
클리닉
병원
기타
세계의 심장대사 질환 시장 : 만성 심부전 및 충혈성 심부전별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
수축기 심부전
확장기 심부전
세계의 심장대사 질환 시장 : 고혈압별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
원발성 고혈압
2차성 고혈압
세계의 심장대사 질환 시장 : 2형 당뇨병별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
인슐린 저항성
내당능 장애
세계의 심장대사 질환 시장 : 비만별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
클래스 I 비만(BMI 30-34.9)
클래스 II 비만(BMI 35-39.9)
클래스 III 비만(BMI 40 이상)
제7장 지역별/국가별 분석
세계의 심장대사 질환 시장 : 지역별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
세계의 심장대사 질환 시장 : 국가별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 프로파일
심장대사 질환 시장 : 경쟁 구도
심장대사 질환 시장 : 기업 프로파일
Pfizer Inc.
Johnson & Johnson
F. Hoffmann-La Roche AG
Merck & Co Inc.
AbbVie Inc.
제31장 기타 주요 기업 및 혁신 기업
Bayer AG
Novartis AG
Sanofi SA
Kowa Company Ltd.
Thermo Fisher Scientific
Abbott Laboratories
Takeda Pharmaceutical Company
Eli Lilly and Company
Novo Nordisk A/S
Siemens Healthineers
Boehringer Ingelheim International GmbH
Becton, Dickinson and Company
Stryker Corporation
AstraZeneca Plc
Viatris Inc.
제32장 세계 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 전략
심장대사 질환 시장(2029년) : 새로운 기회를 제공하는 국가
심장대사 질환 시장(2029년) : 새로운 기회를 제공하는 부문
심장대사 질환 시장(2029년) : 성장 전략
시장 동향에 의한 전략
경쟁 전략
제36장 부록
JHS
영문 목차
영문목차
Cardiometabolic diseases encompass a cluster of interconnected health conditions affecting both the cardiovascular and metabolic systems. These diseases often coexist and share common risk factors such as obesity, sedentary lifestyle, unhealthy diet, and genetic predisposition.
The primary types of cardiometabolic diseases include chronic or congestive heart failure, hypertension, type 2 diabetes, and obesity. Congestive heart failure is a chronic condition where the heart's ability to pump blood efficiently is compromised. Treatment modalities encompass ACE inhibitors, diuretics, glucophage, liposuction, and various therapeutic approaches. Medications are available in tablet and injection forms, administered through various routes such as oral and intravenous. These solutions cater to diverse end-users, including clinics and hospitals.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.
The cardiometabolic diseases market research report is one of a series of new reports from The Business Research Company that provides cardiometabolic diseases market statistics, including cardiometabolic diseases industry global market size, regional shares, competitors with a cardiometabolic diseases market share, detailed cardiometabolic diseases market segments, market trends, and opportunities, and any further data you may need to thrive in the cardiometabolic diseases industry. This cardiometabolic diseases market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The cardiometabolic diseases market size has grown steadily in recent years. It will grow from $111.64 billion in 2024 to $115.27 billion in 2025 at a compound annual growth rate (CAGR) of 3.3%. The growth in the historic period can be attributed to sedentary lifestyles, urbanization and lifestyle shifts, industrialization and processed foods, genetic predispositions, environmental factors.
The cardiometabolic diseases market size is expected to see steady growth in the next few years. It will grow to $136.95 billion in 2029 at a compound annual growth rate (CAGR) of 4.4%. The growth in the forecast period can be attributed to obesity epidemic, aging population continues, healthcare infrastructure development, genomic and precision medicine, chronic stress and mental health. Major trends in the forecast period include health education and awareness, corporate wellness programs, community health programs, prevention-centric healthcare, integrated care approaches.
The forecast of 4.4% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. The imposition of tariffs may disrupt U.S. preventive care by increasing costs for continuous glucose monitors and lipoprotein testing reagents imported from Germany and Finland, potentially worsening diabetes/cardiovascular outcomes. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.
A surge in obesity rates is anticipated to be a significant driver propelling the growth of the cardiometabolic disease market. Obesity, characterized by an excess accumulation of body fat leading to increased body weight, significantly impacts the prevalence of cardiovascular risk factors such as dyslipidemia, type 2 diabetes, hypertension, and sleep disorders. As reported by the World Health Organization (WHO) in March 2022, globally, more than 1 billion individuals grapple with obesity, including 340 million teenagers, 650 million adults, and 39 million children annually. By 2025, the WHO predicts that 167 million adults and children will face health complications stemming from being overweight or obese. This high prevalence of obesity is a pivotal driver fostering the growth of the cardiometabolic diseases market.
The expansion of the aging population is playing a crucial role in bolstering the cardiometabolic diseases market. A growing aging population refers to a demographic shift where the proportion of elderly individuals, typically aged 65 and above, rises in relation to the overall population. Cardiometabolic diseases, encompassing cardiovascular diseases and metabolic disorders such as diabetes, exhibit higher prevalence among older age groups. Aging is accompanied by physiological changes, including metabolic alterations and increased susceptibility to cardiovascular ailments, contributing to the elevated incidence of cardiometabolic diseases in older demographics. For example, data released by the World Health Organization (WHO) in October 2022 indicated a projection of the population aged 60 or above surging from 1 billion in 2020 to 1.4 billion in 2030. Consequently, the burgeoning aging population stands as a significant force driving the cardiometabolic diseases market.
The rising trend within the cardiometabolic diseases market centers on the adoption of cutting-edge technologies. Companies engaged in this sector are actively pursuing innovative technologies to maintain their competitive edge. For example, in February 2023, Eko Health Inc., a US-based innovator in digital health technologies for heart and lung disease detection, introduced the Sensora cardiac disease detection platform. This platform integrates artificial intelligence (AI) capable of accurately detecting structural murmurs, a key indicator of valvular heart disease (VHD). Additionally, the platform incorporates care pathway analytics software, offering valuable metrics and insights into patients' healthcare journeys. The digital stethoscope component of this technology captures and analyzes heartbeats and electrical impulses, enhancing diagnostic capabilities.
Prominent entities operating in the cardiometabolic diseases market are dedicated to developing wearable devices designed for continuous monitoring of patients with cardiometabolic conditions. Continuous monitoring facilitates early detection of cardiometabolic disease symptoms, enabling proactive intervention in the early stages of the disease. For instance, in September 2023, Kilele Health, a healthcare company based in Kenya, unveiled wearable remote continuous patient monitoring specifically tailored for cardiometabolic diseases. This innovation empowers both healthcare professionals and patients by delivering accurate real-time data, thereby enabling timely interventions and improved disease management strategies.
In August 2023, Novo Nordisk, a healthcare company based in Denmark, acquired Embark Biotech for $498 million. This acquisition is intended to strengthen Novo Nordisk's pipeline for treating obesity and other cardiometabolic diseases. Embark Biotech, also located in Denmark, has developed therapies for various cardiometabolic conditions, including obesity and type 2 diabetes.
Major companies operating in the cardiometabolic diseases market include Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche AG, Merck & Co Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi SA, Kowa Company Ltd., Thermo Fisher Scientific, Abbott Laboratories, Takeda Pharmaceutical Company, Eli Lilly and Company, Novo Nordisk A/S, Siemens Healthineers, Boehringer Ingelheim International GmbH, Becton, Dickinson and Company, Stryker Corporation, AstraZeneca Plc, Viatris Inc., Biocrates Life Sciences AG, Boston Scientific, Astellas Pharma Inc., Terumo Corporation, Agilent Technologies, Edwards Lifesciences, Bruker Corporation, Alnylam Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., Cardax Inc.
North America was the largest region in the cardiometabolic diseases market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cardiometabolic diseases market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the cardiometabolic diseases market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The cardiometabolic diseases market consists of revenues earned by entities by providing services such as non-invasive CAD testing, cardio-preventive care, behavioral counseling, and clinical assessment. The market value includes the value of related goods sold by the service provider or included within the service offering. The cardiometabolic diseases market also includes sales of medications, blood glucose monitoring devices, blood pressure monitors, cholesterol testing kits, and weight management products used to provide cardiometabolic diseases services. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Cardiometabolic Diseases Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on cardiometabolic diseases market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for cardiometabolic diseases ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The cardiometabolic diseases market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Type: Chronic Or Congestive Heart Failure, Hypertension, Type 2 Diabetes, Obesity
2) By Treatment: ACE inhibitors, Diuretics, Glucophage, Liposuction, Other Treatments
3) By Dosage: Tablet, Injection
4) By Route Of Administration: Oral, Intravenous, Other Routes Of Administration
5) By End-Users: Clinic, Hospital, Other End-Users
Subsegments:
1) By Chronic Or Congestive Heart Failure: Systolic Heart Failure; Diastolic Heart Failure
2) By Hypertension: Primary Hypertension; Secondary Hypertension
3) By Type 2 Diabetes: Insulin Resistance; Impaired Glucose Tolerance
4) By Obesity: Class I Obesity (BMI 30-34.9); Class II Obesity (BMI 35-39.9); Class III Obesity (BMI 40 And above)
Companies Mentioned: Pfizer Inc.; Johnson & Johnson; F. Hoffmann-La Roche AG; Merck & Co Inc.; AbbVie Inc.; Bayer AG; Novartis AG; Sanofi SA; Kowa Company Ltd.; Thermo Fisher Scientific; Abbott Laboratories; Takeda Pharmaceutical Company; Eli Lilly and Company; Novo Nordisk A/S; Siemens Healthineers; Boehringer Ingelheim International GmbH; Becton, Dickinson and Company; Stryker Corporation; AstraZeneca Plc; Viatris Inc.; Biocrates Life Sciences AG; Boston Scientific; Astellas Pharma Inc.; Terumo Corporation; Agilent Technologies; Edwards Lifesciences; Bruker Corporation; Alnylam Pharmaceuticals Inc.; Arrowhead Pharmaceuticals Inc.; Cardax Inc.
3. Cardiometabolic Diseases Market Trends And Strategies
4. Cardiometabolic Diseases Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
4.1. Supply Chain Impact from Tariff War & Trade Protectionism
5. Global Cardiometabolic Diseases Growth Analysis And Strategic Analysis Framework
5.1. Global Cardiometabolic Diseases PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Cardiometabolic Diseases Market Growth Rate Analysis
5.4. Global Cardiometabolic Diseases Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Cardiometabolic Diseases Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Cardiometabolic Diseases Total Addressable Market (TAM)
6. Cardiometabolic Diseases Market Segmentation
6.1. Global Cardiometabolic Diseases Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Chronic Or Congestive Heart Failure
Hypertension
Type 2 Diabetes
Obesity
6.2. Global Cardiometabolic Diseases Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
ACE inhibitors
Diuretics
Glucophage
Liposuction
Other Treatments
6.3. Global Cardiometabolic Diseases Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Tablet
Injection
6.4. Global Cardiometabolic Diseases Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral
Intravenous
Other Routes Of Administration
6.5. Global Cardiometabolic Diseases Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Clinic
Hospital
Other End-Users
6.6. Global Cardiometabolic Diseases Market, Sub-Segmentation Of Chronic Or Congestive Heart Failure, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Systolic Heart Failure
Diastolic Heart Failure
6.7. Global Cardiometabolic Diseases Market, Sub-Segmentation Of Hypertension, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Primary Hypertension
Secondary Hypertension
6.8. Global Cardiometabolic Diseases Market, Sub-Segmentation Of Type 2 Diabetes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Insulin Resistance
Impaired Glucose Tolerance
6.9. Global Cardiometabolic Diseases Market, Sub-Segmentation Of Obesity, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Class I Obesity (BMI 30-34.9)
Class II Obesity (BMI 35-39.9)
Class III Obesity (BMI 40 And above)
7. Cardiometabolic Diseases Market Regional And Country Analysis
7.1. Global Cardiometabolic Diseases Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Cardiometabolic Diseases Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
